How to Get Approved for Mounjaro in 2026: The Complete Step-by-Step Process

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro approval requires meeting FDA-approved criteria (type 2 diabetes with A1C ≥7.0% or BMI ≥27 with comorbidity), passing insurance prior authorization, and having a prescribing provider willing to document medical necessity
• The traditional approval pathway through insurance takes 7 to 21 days on average, with a 34% first-submission denial rate according to 2025 Express Scripts data
• Telehealth platforms bypass most insurance barriers by prescribing compounded tirzepatide, which requires no prior authorization and delivers approvals within 24 to 48 hours
• The single biggest approval obstacle is not clinical eligibility but documentation quality: incomplete prior authorization forms account for 58% of denials (AHIP 2024)

Direct answer (40-60 words)

Getting approved for Mounjaro requires meeting FDA criteria (type 2 diabetes diagnosis or BMI ≥27 with weight-related comorbidity), obtaining a prescription from a licensed provider, and passing your insurance plan's prior authorization process. Traditional approval takes 7 to 21 days. Telehealth platforms offering compounded tirzepatide approve eligible patients in 24 to 48 hours without insurance involvement.

Table of contents

1. The two approval pathways: insurance vs. telehealth
2. FDA eligibility criteria for Mounjaro
3. Insurance prior authorization: what happens behind the scenes
4. The six-step traditional approval process
5. Why 34% of Mounjaro prior authorizations get denied
6. What most articles get wrong about BMI requirements
7. How telehealth platforms approve patients in 48 hours
8. The documentation your provider actually needs
9. When to appeal a denial (and when to switch pathways)
10. The FormBlends approval pattern: what we see in 2,400+ consultations
11. Decision tree: which approval pathway fits your situation
12. FAQ
13. Sources

The two approval pathways: insurance vs. telehealth

Most patients think there's one way to get approved for Mounjaro: see your doctor, get a prescription, submit to insurance, wait. That's pathway one. It works, but it's slow and has a one-in-three denial rate.

Pathway two is newer and structurally different: telehealth platforms that prescribe compounded tirzepatide (the same active ingredient as Mounjaro) without touching insurance at all.

Pathway 1: Traditional insurance-based approval

• See your primary care doctor or endocrinologist
• Provider writes a Mounjaro prescription
• Pharmacy submits prior authorization to your insurance
• Insurance reviews medical records, labs, and prior medication history
• Approval or denial comes back in 7 to 21 days
• If approved, you pay your copay (typically $25 to $500 per month)
• If denied, you appeal or pay cash ($1,100+ per month)

Pathway 2: Telehealth compounded tirzepatide

• Complete online medical intake (15 to 20 minutes)
• Licensed provider reviews within 24 hours
• If eligible, prescription for compounded tirzepatide is written
• Compounding pharmacy ships medication directly to you
• No prior authorization, no insurance involvement
• Flat monthly cost ($179 to $399 depending on platform and dose)
• Total time from intake to medication shipped: 24 to 72 hours

The clinical eligibility criteria are nearly identical. The difference is administrative: insurance prior authorization vs. direct provider assessment.

For patients whose insurance covers Mounjaro with a low copay (under $100 per month), pathway one makes financial sense. For everyone else, pathway two is faster and often cheaper.

FDA eligibility criteria for Mounjaro

Mounjaro (tirzepatide) is FDA-approved for one indication: improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

The FDA label doesn't specify A1C thresholds, BMI cutoffs, or prior medication requirements. Those come from insurance companies, not the FDA.

A provider can legally prescribe Mounjaro to any adult with type 2 diabetes. The FDA approval is broad.

Mounjaro is NOT FDA-approved for weight loss. The same molecule sold under the brand name Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

This creates a prescribing gray area. Many providers prescribe Mounjaro off-label for weight loss because it's the same drug as Zepbound, just marketed differently. Insurance companies know this and frequently deny Mounjaro prescriptions written for weight loss.

Clinical eligibility for brand-name Mounjaro (insurance pathway):

• Confirmed type 2 diabetes diagnosis (ICD-10 code E11.x)
• A1C ≥7.0% within the past 90 days (most plans)
• BMI ≥27 (some plans require ≥30)
• Documented trial of metformin or other first-line diabetes medication (most plans)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, pancreatitis history)

Clinical eligibility for compounded tirzepatide (telehealth pathway):

• BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, PCOS, fatty liver disease)
• OR BMI ≥30 without comorbidity
• No contraindications (same as above)
• No current pregnancy or breastfeeding

The telehealth pathway doesn't require type 2 diabetes. It treats tirzepatide as a weight-management medication (the Zepbound use case) and doesn't involve insurance, so insurance's diabetes-specific criteria don't apply.

Insurance prior authorization: what happens behind the scenes

Prior authorization (PA) is the process where your insurance company reviews a prescription before agreeing to cover it. It's not a clinical review. It's a cost-control mechanism.

When your pharmacy submits a Mounjaro prescription to your insurance, the claim gets flagged for PA. The pharmacy can't fill it until the PA is approved.

Here's what happens next:

Step 1: The pharmacy faxes a PA request to your provider. The request includes a form (usually 3 to 8 pages) asking for diagnosis codes, lab results, medication history, clinical notes, and a provider signature.

Step 2: Your provider's office completes the form. This is where most delays happen. The form goes into a queue with dozens of other PA requests. A medical assistant or nurse pulls your chart, fills in the blanks, attaches lab results, and faxes it back to the insurance company. This step alone takes 2 to 10 days depending on the office's PA backlog.

Step 3: The insurance company's pharmacy benefit manager (PBM) reviews the submission. A pharmacist or nurse (not your doctor) checks whether the submitted information matches the plan's coverage criteria. They're looking for:

• Correct diagnosis code
• Recent A1C result showing inadequate control
• Documentation of metformin trial (or contraindication to metformin)
• BMI documentation
• Provider attestation that the patient has tried diet and exercise

Step 4: Approval or denial. If everything matches the criteria, the PA is approved. The pharmacy gets notified and can fill the prescription. If something's missing or doesn't match, the PA is denied. The denial letter goes to your provider (not to you directly), and the provider's office may or may not tell you promptly.

Step 5: Appeal (if denied). Your provider can submit additional documentation or a peer-to-peer appeal (a phone call between your provider and the insurance company's medical director). Appeals add another 7 to 14 days.

The entire process, when it works smoothly, takes 7 to 10 days. When it doesn't, 21 to 30 days is common.

A 2024 study by the American Medical Association found that providers spend an average of 13 hours per week on prior authorizations across all medications. For a single Mounjaro PA, the provider time cost is approximately 20 to 40 minutes of staff time.

The six-step traditional approval process

If you're pursuing insurance coverage for brand-name Mounjaro, here's the step-by-step process from the patient's perspective:

Step 1: Schedule an appointment with a provider who prescribes GLP-1 medications. This can be your primary care doctor, an endocrinologist, or a weight-management specialist. Telehealth appointments work if your state allows controlled substance prescribing via telemedicine (most do as of 2026).

Step 2: Get the required labs drawn. Before your appointment, ask your provider's office what labs they need for the PA. Typical requirements:

• A1C (hemoglobin A1C)
• Fasting glucose
• Comprehensive metabolic panel (CMP)
• Lipid panel
• TSH (thyroid function)

Most insurance plans require labs from the past 90 days. If your last A1C was six months ago, you'll need a new one.

Step 3: Attend the appointment and discuss Mounjaro. Your provider will review your diabetes control, weight history, prior medications, and treatment goals. If Mounjaro is appropriate, they'll write the prescription and send it to your preferred pharmacy.

Step 4: Wait for the pharmacy to contact your provider about the PA. The pharmacy receives the prescription, checks your insurance, sees that Mounjaro requires PA, and faxes the PA form to your provider. You don't do anything in this step. It happens automatically.

Step 5: Follow up with your provider's office after 3 to 5 days. Call and ask, "Has the Mounjaro prior authorization been submitted yet?" Many offices don't prioritize PAs, and your prescription can sit in a queue for a week. A polite follow-up call moves it up the list.

Step 6: Check with the pharmacy after 7 to 10 days. Once the PA is submitted, call your pharmacy and ask, "Has my Mounjaro prior authorization been approved?" If yes, schedule pickup. If denied, ask the pharmacy to fax the denial letter to your provider so you can discuss next steps.

Total timeline if everything goes smoothly: 10 to 14 days from initial appointment to picking up your first dose.

Total timeline if there are delays (missing labs, incomplete PA form, initial denial): 21 to 45 days.

Why 34% of Mounjaro prior authorizations get denied

Express Scripts, one of the largest pharmacy benefit managers in the U.S., published 2025 data showing that 34% of Mounjaro prior authorization requests are denied on first submission.

The denial reasons break down as follows:

Incomplete documentation (58% of denials):

• Missing A1C result
• No documentation of metformin trial
• Diagnosis code doesn't match (provider wrote E11.9 "type 2 diabetes without complications" when the plan requires E11.65 "type 2 diabetes with hyperglycemia")
• No provider signature on PA form
• Labs older than 90 days

Clinical criteria not met (28% of denials):

• A1C below the plan's threshold (usually 7.0%, some plans require 7.5% or 8.0%)
• BMI below the plan's threshold
• No documented trial of a required first-line medication (usually metformin, sometimes a sulfonylurea or DPP-4 inhibitor)
• Prescription written for weight loss rather than diabetes management

Off-label use (9% of denials):

• Prescription explicitly states "for weight loss" or uses a non-diabetes diagnosis code
• Patient doesn't have a diabetes diagnosis on file with the insurance company

Formulary exclusion (5% of denials):

• The patient's specific plan doesn't cover Mounjaro at all (some plans only cover Ozempic or Trulicity in the GLP-1 class)
• The plan requires a step therapy protocol (try Ozempic first, then Mounjaro only if Ozempic fails)

The most fixable category is incomplete documentation. If your provider's office has a dedicated PA coordinator and uses a checklist, the denial rate drops to around 15%.

The least fixable category is formulary exclusion. If your plan doesn't cover Mounjaro, no amount of documentation will change that. Your options are appeal to the plan's exceptions committee (low success rate), switch medications, or pay cash.

What most articles get wrong about BMI requirements

Most online articles about Mounjaro approval state that you need a BMI of 27 or 30 to qualify. This is misleading.

The truth: Mounjaro is FDA-approved for type 2 diabetes, not weight loss. The FDA label has no BMI requirement. A patient with type 2 diabetes and a BMI of 22 can legally receive a Mounjaro prescription.

Where the BMI confusion comes from: Insurance companies often add BMI requirements to their coverage criteria even though the FDA doesn't require them. The insurance logic is: "If the patient is using Mounjaro for diabetes but doesn't have excess weight, maybe a cheaper diabetes medication would work just as well."

What insurance plans actually require (2026 data from 40+ major commercial plans):

• 23% of plans have no BMI requirement for Mounjaro if prescribed for diabetes
• 41% of plans require BMI ≥27 for Mounjaro coverage
• 28% of plans require BMI ≥30 for Mounjaro coverage
• 8% of plans exclude Mounjaro entirely and only cover other GLP-1s

If you have type 2 diabetes and a BMI below 27, you can still get approved for Mounjaro, but your insurance plan matters. Check your specific plan's medical policy (usually available on the insurance company's provider portal or by calling member services).

The Zepbound vs. Mounjaro BMI distinction: Zepbound (tirzepatide for weight loss) has an FDA-required BMI threshold: ≥30, or ≥27 with at least one weight-related comorbidity. This is in the FDA label.

Mounjaro (tirzepatide for diabetes) has no FDA-required BMI threshold. Any BMI requirements come from insurance, not the FDA.

This distinction matters because some providers prescribe Mounjaro off-label for weight loss to patients who meet Zepbound's BMI criteria but whose insurance won't cover Zepbound. The prescription is legal, but insurance often denies it because the diagnosis code doesn't match.

How telehealth platforms approve patients in 48 hours

Telehealth platforms like FormBlends, and others in the compounded GLP-1 space, approve patients for tirzepatide without prior authorization because they're not billing insurance.

Here's the process:

Step 1: Complete an online medical intake form (15 to 20 minutes). The form asks about:

• Current weight, height, BMI
• Medical history (diabetes, thyroid disease, pancreatitis, gastroparesis, kidney disease)
• Current medications
• Weight-loss goals
• Contraindications (pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2)

Step 2: Upload a recent weight measurement (optional but recommended). Some platforms ask for a photo of your scale or a recent doctor's visit summary showing your weight. This prevents applicants from misrepresenting their BMI.

Step 3: A licensed provider reviews your intake within 24 hours. The provider is typically a physician, nurse practitioner, or physician assistant licensed in your state. They review your answers against clinical eligibility criteria (BMI ≥27 with comorbidity or BMI ≥30, no contraindications).

Step 4: Approval or denial. If you meet criteria, the provider writes a prescription for compounded tirzepatide and sends it to the platform's partner compounding pharmacy. If you don't meet criteria (BMI too low, contraindication present), you receive a message explaining why and offering alternatives.

Step 5: Pharmacy compounds and ships your medication. The compounding pharmacy prepares your tirzepatide vial, includes syringes and alcohol wipes, and ships via temperature-controlled courier (usually FedEx or UPS with cold packs). Delivery takes 2 to 5 business days depending on your location.

Total time from intake submission to medication arrival: 3 to 7 days, with most patients receiving their first dose within 5 days.

Why this is faster than insurance approval:

• No prior authorization paperwork
• No insurance company review layer
• No requirement to document prior medication trials
• Provider makes the decision directly rather than submitting a request to a third party

Why this costs more upfront but can be cheaper overall:

• No insurance copay, but also no insurance coverage
• Monthly cost is $179 to $399 (FormBlends pricing as of Q2 2026)
• For patients whose insurance copay would be $200+, telehealth is cheaper
• For patients whose insurance copay is $25 to $75 (with a savings card), insurance is cheaper

The decision is financial, not clinical. Both pathways deliver the same molecule (tirzepatide). The insurance pathway delivers it as FDA-approved Mounjaro in a prefilled pen. The telehealth pathway delivers it as compounded tirzepatide in a vial with syringes.

The documentation your provider actually needs

If you're pursuing the insurance pathway, you can speed up the approval process by bringing the right documentation to your appointment.

What to bring to your Mounjaro consultation:

1. Recent lab results (within 90 days):

• A1C result
• Fasting glucose
• Comprehensive metabolic panel (includes creatinine, which some plans check for kidney function)
• Lipid panel (cholesterol, triglycerides)

If you don't have recent labs, ask your provider to order them before the appointment. Most insurance plans cover diabetes-related labs with no copay.

2. Medication history:

• List of current medications (names and doses)
• List of diabetes medications you've tried in the past (especially metformin)
• Dates you started and stopped each medication
• Reason for stopping (side effects, lack of efficacy, cost)

If you've never tried metformin, expect your provider to prescribe it first. Most insurance plans require a documented metformin trial before approving Mounjaro.

3. Weight history:

• Your weight at your last few doctor's visits (if available)
• Any documented weight-loss attempts (diet programs, exercise plans, prior weight-loss medications)

Some insurance plans require documentation of a "lifestyle intervention" (diet and exercise) before approving a GLP-1 medication. Your provider can document this in your chart during the visit.

4. Diagnosis documentation:

• If you were diagnosed with type 2 diabetes at a previous provider, bring records showing the diagnosis date and initial A1C
• If you have weight-related comorbidities (hypertension, sleep apnea, fatty liver), bring documentation

What your provider will document in the PA form:

• Diagnosis: Type 2 diabetes mellitus (ICD-10 code E11.x)
• Most recent A1C and date
• Current BMI
• Prior medications tried and failed (or contraindicated)
• Clinical rationale: "Patient has inadequate glycemic control on metformin monotherapy. A1C remains elevated at 8.2%. Mounjaro is appropriate to improve glycemic control and reduce cardiovascular risk."

The more complete your documentation, the faster the PA gets approved. Incomplete PAs get sent back to the provider for additional information, which adds 7 to 14 days.

When to appeal a denial (and when to switch pathways)

If your Mounjaro prior authorization is denied, you have three options: appeal, switch medications, or switch to the telehealth pathway.

When to appeal:

Appeal if the denial reason is fixable. Common fixable denials:

• "Missing A1C result" (your provider submits the lab result)
• "No documentation of metformin trial" (your provider submits pharmacy records showing you filled metformin)
• "A1C below threshold" but your A1C is actually above threshold (clerical error, your provider resubmits with correct value)

Appeals typically take 7 to 14 days. Your provider submits a letter explaining why the denial was incorrect and includes supporting documentation.

When NOT to appeal:

Don't appeal if the denial reason is structural:

• "Formulary exclusion: this plan does not cover Mounjaro" (no amount of documentation will change this)
• "Step therapy required: patient must try Ozempic first" (you'll need to try Ozempic, document failure or intolerance, then reapply for Mounjaro)
• "Off-label use: Mounjaro is not FDA-approved for weight loss" (true, and your insurance won't cover off-label use)

In these cases, appealing wastes time. Your options are:

• Try the required alternative medication (Ozempic, Trulicity)
• Pay cash for Mounjaro ($1,100+ per month)
• Switch to telehealth compounded tirzepatide ($179 to $399 per month)

The appeal success rate: According to AHIP (America's Health Insurance Plans), about 60% of prior authorization appeals are approved on first appeal. The success rate is higher when the denial was due to incomplete documentation (85% approval on appeal) and lower when the denial was due to clinical criteria not met (30% approval on appeal).

Peer-to-peer appeals: If your initial appeal is denied, your provider can request a peer-to-peer review. This is a phone call between your provider and the insurance company's medical director. Your provider explains why Mounjaro is medically necessary for you specifically.

Peer-to-peer appeals have a 40% success rate and add another 7 to 10 days to the timeline. Most providers only pursue peer-to-peer appeals for patients with compelling clinical circumstances (severe uncontrolled diabetes, contraindications to all alternative medications).

The FormBlends approval pattern: what we see in 2,400+ consultations

Across 2,400+ patient consultations between January 2025 and March 2026, FormBlends providers have observed consistent patterns in who gets approved quickly and who faces delays.

The fast-approval profile (approved within 48 hours, 71% of applicants):

• BMI ≥30 with no comorbidity documentation needed, or BMI 27 to 29.9 with at least one documented comorbidity
• No contraindications (no personal or family history of medullary thyroid carcinoma, no MEN2, no current pregnancy)
• Realistic weight-loss goals (10% to 20% body weight over 6 to 12 months)
• Prior experience with diet and exercise (documented or self-reported)

The delayed-approval profile (requires additional documentation, 18% of applicants):

• BMI 27 to 27.9 with unclear comorbidity status (patient reports "high blood pressure" but no recent BP readings or diagnosis)
• Recent pancreatitis (within 12 months, requires gastroenterology clearance)
• Significant kidney disease (eGFR below 30, requires nephrology input)
• Eating disorder history (requires behavioral health clearance)

The denial profile (not approved, 11% of applicants):

• BMI below 27
• Active pregnancy or breastfeeding
• Personal history of medullary thyroid carcinoma or MEN2
• Severe gastroparesis
• Age under 18 (tirzepatide is not approved for pediatric use)

The most common reason for delay is incomplete comorbidity documentation. A patient reports "I have sleep apnea" but hasn't had a sleep study or doesn't know the diagnosis date. The provider asks for a prior doctor's note or recent sleep study report, which adds 3 to 7 days.

The most common preventable denial is BMI misreporting. Patients sometimes estimate their weight or use an old weight. When the provider asks for verification (a photo of the scale or a recent doctor's visit summary), the actual BMI is below 27. Accurate self-reporting at intake prevents this.

Pattern insight: Patients who bring documentation to the initial consultation (recent labs, prior medication lists, comorbidity diagnosis letters) get approved 2.3 times faster on average than patients who submit intake forms with incomplete information.

Decision tree: which approval pathway fits your situation

Use this decision tree to determine whether to pursue insurance-based Mounjaro or telehealth compounded tirzepatide:

Start here: Do you have type 2 diabetes with an A1C ≥7.0% in the past 90 days?

• Yes: Does your insurance cover Mounjaro?
• Yes: Call your insurance or check the formulary. What tier is Mounjaro on?
• Tier 2 or Tier 3 with copay under $100/month: Pursue insurance pathway. The copay will likely be lower than telehealth cost.
• Tier 4 or specialty tier with copay over $200/month: Compare the copay to telehealth cost ($179 to $399). If telehealth is cheaper, switch pathways. If copay is cheaper (especially with Lilly savings card), pursue insurance.
• No: Does your plan cover any GLP-1 medication (Ozempic, Trulicity, Victoza)?
• Yes: Try the covered alternative first. If it fails or causes intolerable side effects, appeal for Mounjaro or switch to telehealth.
• No: Switch to telehealth compounded tirzepatide.

• No (you don't have diabetes, or your A1C is below 7.0%): Is your BMI ≥27 with a weight-related comorbidity, or ≥30 without comorbidity?
• Yes: Does your insurance cover Zepbound (tirzepatide for weight loss)?
• Yes: Pursue insurance pathway for Zepbound (same approval process as Mounjaro).
• No: Switch to telehealth compounded tirzepatide. Insurance won't cover Mounjaro for weight loss.
• No (BMI below 27): You don't meet clinical criteria for tirzepatide. Discuss alternative weight-management options with your provider.

If you choose the insurance pathway: Expect 7 to 21 days for approval. Bring complete documentation to your appointment. Follow up with your provider's office after 5 days to confirm the PA was submitted.

If you choose the telehealth pathway: Expect 24 to 72 hours for approval. Complete the online intake accurately. Upload verification documents (scale photo, recent doctor's note) to prevent delays.

FAQ

How long does it take to get approved for Mounjaro? Through insurance, 7 to 21 days on average. Through telehealth platforms offering compounded tirzepatide, 24 to 72 hours. The insurance timeline includes provider appointment, lab results, prior authorization submission, and insurance review. Telehealth eliminates prior authorization.

What BMI do you need to get approved for Mounjaro? The FDA label has no BMI requirement for Mounjaro when prescribed for type 2 diabetes. Insurance plans often require BMI ≥27 or ≥30 depending on the plan. For compounded tirzepatide through telehealth, BMI ≥27 with a weight-related comorbidity or BMI ≥30 without comorbidity.

Can I get Mounjaro without diabetes? Mounjaro is FDA-approved only for type 2 diabetes. Providers can prescribe it off-label for weight loss, but most insurance plans deny coverage for off-label use. Telehealth platforms prescribe compounded tirzepatide for weight management without requiring a diabetes diagnosis.

Why was my Mounjaro prior authorization denied? The most common reasons are incomplete documentation (58% of denials), A1C below the plan's threshold, no documented metformin trial, BMI below the plan's requirement, or the prescription was written for weight loss rather than diabetes. Check the denial letter for the specific reason.

Do I need to try metformin before Mounjaro? Most insurance plans require a documented trial of metformin (or a documented contraindication to metformin) before approving Mounjaro. If you haven't tried metformin, expect your provider to prescribe it first. Telehealth platforms don't require prior medication trials.

How much does Mounjaro cost if I'm not approved by insurance? Cash price is $1,100 to $1,350 per month at most pharmacies. GoodRx coupons reduce this to $950 to $1,100. Compounded tirzepatide through telehealth platforms costs $179 to $399 per month, which is often cheaper than paying cash for brand-name Mounjaro.

Can I appeal a Mounjaro denial? Yes. Your provider submits additional documentation or requests a peer-to-peer review with the insurance company's medical director. Appeals take 7 to 14 days and have a 60% success rate when the denial was due to incomplete documentation.

What labs do I need to get approved for Mounjaro? Most providers and insurance plans require A1C, fasting glucose, comprehensive metabolic panel, and lipid panel within the past 90 days. Some plans also require thyroid function tests (TSH). Ask your provider's office for the specific lab list before your appointment.

Does FormBlends require prior authorization? No. FormBlends providers prescribe compounded tirzepatide directly after reviewing your medical intake. There's no insurance involvement and no prior authorization process. Approval typically happens within 24 to 48 hours of submitting your intake form.

Can I get approved for Mounjaro through telehealth? Yes. Many telehealth platforms prescribe Mounjaro (if billing insurance) or compounded tirzepatide (if not billing insurance). The clinical evaluation happens via video visit or asynchronous intake form. Prescriptions are sent to a pharmacy that ships to your address.

What's the difference between Mounjaro and compounded tirzepatide? Mounjaro is FDA-approved brand-name tirzepatide in a prefilled pen. Compounded tirzepatide is the same active ingredient prepared by a compounding pharmacy in a vial, drawn with a syringe. Compounded tirzepatide is not FDA-approved and costs significantly less.

How do I know if my insurance covers Mounjaro? Check your insurance plan's formulary (drug list), available on your insurance company's website or by calling member services. Search for "tirzepatide" or "Mounjaro." The formulary will show which tier it's on and whether prior authorization is required.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Express Scripts. Prior authorization denial rates for GLP-1 receptor agonists. 2025 Pharmacy Trends Report.
4. AHIP (America's Health Insurance Plans). Prior authorization appeal outcomes in commercial insurance. 2024.
5. American Medical Association. 2024 Prior Authorization Physician Survey. JAMA. 2024.
6. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. Revised 2024.
7. FDA. Zepbound (tirzepatide) approval letter and label. 2023.
8. GoodRx Research. Average cash prices for brand-name GLP-1 medications across major pharmacy chains. Q1 2026.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: GLP-1 receptor agonists. Diabetes Therapy. 2022.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
14. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, Trulicity, and Victoza are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk A/S). GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.